Lonza has expanded its human primary cell offerings with the launch of customizable cryopreserved Leukopaks. The frozen Leukopaks enable long-distance shipping of leukapheresis products without the concern of reduced cell viability encountered with fresh Leukopaks. Suitable for long-term storage in research labs, the cryopreserved Leukopaks also allow immediate access to viable cells for greater convenience and workflow flexibility, according to the company. The cryopreserved Leukopaks come in a...